Captiva Verde Comprehensive Update

Captiva Verde Land Corp. (CSE: PWR) (OTC: CPIVF) (the “Company”), is pleased to report an update on all of our major operating business segments plus our recommendation of a financial newsletter written by an award winning portfolio manager.

Financial Newsletter – Grit Capital
Captiva Verde sponsored an investor event in Las Vegas in December 2019 with Grit Capital. Beginning November 1, 2020, Grit Capital has launched a very efficient and easy to read, fun, exceedingly informative, and highly impactful Investment Newsletter that covers emerging trends, themes and investment ideas which is based on where big money and momentum is moving in the market, long before the general investing public studies the available information. The newsletter is written by Genevieve Roch-Decter, CFA, a former $100 Million+ small cap portfolio manager who’s fund was ranked #1 for 3 of the 7 years she ran it (as ranked by Globe & Mail – GlobeFunds). We strongly recommend all of our shareholders and all interested friends and family to subscribe to the free newsletter at https://gritcapital.substack.com

Solargram Farms (“SGF”)
SGF just completed its 1st year harvest in Renauds Mills NB, growing 13,000 plants over approximately 20 acres within its Health Canada 50 acre licensed outdoor cannabis cultivation footprint (total 130 acres land package for future expansion). SGF averaged 1 person per acre from the grow team to grow the first year harvest and made approximately 95% of the operating costs, variable costs.

SGF obtained its cultivation license on June 26th in the middle of the Covid19 Pandemic and successfully planted, nurtured, and subsequently finished the fall harvest last Sunday. SGF has harvested approximately 16,000kg of cannabis which will yield approximately 3800kg of dried cannabis. SGF has purposely planned produced approximately 500 to 600kg of cured dried flower within the larger harvested product this year, that is destined for bulk sales to customers over the next 4 to 6 weeks that will commence the monetization of sales. This initial planned sales represents less than 15% of the harvest volume that will generate over $1.6 million in sales that is expected to cover all of the 2021 forecasted operating expenses before commencing producing the much higher valued, oil extracted based cannabis products that have been requested by our customers.

The balance of the harvested product has now been milled and will be sent to the extraction partner for oil processing as soon as SGF’s obtains the Health Canada sales and processing license which is expected within six weeks. This processed oil extract will allow SGF to produce planned scheduled products that will satisfy the customer’s request for product. The first year estimated sales will be in excess of $15,000,000 starting early 2021 at a forecast 60-70% gross margin. The two main harvested genetics which comprises 85% of the crop has initially tested 19%-22% THC which is a major win for such a large outdoor grown crop. Further broader representative sample testing will be done once the harvest is completely dried within another week which we expect will be within the same relevant range previously obtained.

SGF’s has commenced growing the 2021 season mothers and clones and expects to produce 20,000 plants with very low additional capital costs, expecting that will in fact more than double the 2021 production yield and sales on the same 2020 production footprint.

We remain a debt free company and, as a result, will be able to provide shareholders with a significant return on investment once sales and profitability materializes in 2021.

Sage Ranch
The final Planning Commission approval looks like it will be on December 9. After that date we wait 45 days and we can begin construction. We have over 200 families on the waiting list to purchase homes and we have engaged Keller Williams – Paul Morris Forward Living to sell our remaining units to the 1 million people who live within a 40 minute drive and a further 25 million people who live within a 2 hour drive of the subdivision.

We expect the entire 1,000 units ($400 Million) to sell out and this upcoming Planning Commission approval is a game changing event. Entry Level Real Estate prices have soared and demand is very high as California is short 2.4 million entry level homes.

Esmeralda
Our new pharmaceutical manufacturing plant structure is completed. We have 3 more weeks of electrical, plumbing and finishing touches. We have generated an equipment list and the final step is purchasing and installing the manufacturing equipment. We expect this completed by year end which is to fulfil our USD $142 Million yearly sales contract with the Health Care Workers Union.

Miss Envy
We have designed some product for Asia and getting very positive feedback on the product quality. Working towards the next steps of larger acceptance by various groups in Asia. Miss Envy is providing both Mexico (Esmeralda) and Solargram with product strategies and assistance in preparing for revenue sales in both Canada and Mexico.

On Behalf of the Board of Directors
“Jeffrey Ciachurski”
Jeffrey Ciachurski
Chief Executive Officer and Director
Cell: (949) 903-5906
E-mail: westernwind@shaw.ca

Cautionary Note Regarding Forward-Looking Information
This release includes certain statements that may be deemed “forward-looking statements”. All statements in this release, other than statements of historical facts, that address events or developments that the Company expects to occur, are forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words “expects”, “plans”, “anticipates”, “believes”, “intends”, “estimates”, “projects”, “potential” and similar expressions, or that events or conditions “will”, “would”, “may”, “could” or “should” occur. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in the forward-looking statements. Factors that could cause the actual results to differ materially from those in forward-looking statements include regulatory actions, market prices, and continued availability of capital and financing, and general economic, market or business conditions.

Investors are cautioned that any such statements are not guarantees of future performance and actual results or developments may differ materially from those projected in the forward-looking statements. Forward-looking statements are based on the beliefs, estimates and opinions of the Company’s management on the date the statements are made. Except as required by applicable securities laws, the Company undertakes no obligation to update these forward-looking statements in the event that management’s beliefs, estimates or opinions, or other factors, should change.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/67309

Valarhash Launches New Service Series for its Mining Hosting Operations

Valarhash, a leader in digital asset services, officially launches a new series of cryptocurrency miner hosting services, now enabling customers with remote online access to the operations of their mining machines. Registered users will have many features such as selecting their mining pool, withdrawing options and even re-selling their mining machine on the platform. Customers can purchase machines from Valarhash or other providers and have them shipped to the Valarhash mining farms.

Valarhash is launching the new service series following an earlier announcement launching miner machine hosting plans. With versatility being of the utmost importance, Valarhash adds the new series of features in order to distinguish itself from its counterparts. The Valarhash mining pool charges a handling fee of 2%, and users are free to assign a designated mining pool for their mining machine based on their needs, offering a customizable experience. This ensures a reliable supply of computing power to consumers which can be viewed in real-time via an app or web management system built by the platform.

Kevin Huang, co-founder of Valarhash, said “given that higher BTC prices would result in a rise in the price of a mining machine, we have decided to allow users to opt out of the hosting services and to re-sell their machines and computing power at any time.” Valarhash hosts a large mining community and manages 100,000 mining machines in its facilities, with maintenance available 24/7. In order to respond promptly to glitches and other concerns, on-site operations and repairs will be carried out by Valarhash staff as they occur, without the need for customers to pay fees in advance.

Valarhash, with its large scale operations, is able to standardize procedures and regulate mining costs because of its longstanding partnerships with local power stations. Customers can take advantage of the Valarhash hosting service for an annual fee of $0.046 (KW/H), in comparison to the rates provided on other sites where the annual fee is $0.055 (KW/H) and above. This hosting fee is inclusive of both the operating and maintenance costs of the mining machines.

For information about the new services, please visit our official website to get in touch with a representative.

Website: https://www.valarhash.com
Twitter: https://twitter.com/VaIarhash
Facebook: https://www.facebook.com/Valarhash
Linkedin: https://www.linkedin.com/company/vhash/
Medium: https://medium.com/@Valarhash
Telegram: https://t.me/valarhashx1tmine

About Valarhash
Chengdu-based Valarhash integrates mining machine sales, miner hosting, mining pool and mine construction services. Led by CEO Fiona Lv, Valarhash aims to provide users with transparent and beneficial mining plans using advanced technology, with a lower barrier of entry. Business operations cover hardware research and development, digital asset transactions and 1TMine hash power contract sharing. With a leading position in the hash power market, Valarhash integrates frontier resources with global vision, providing crypto compute service (CCS) and linking physical and digital worlds with blockchain technology. Email: BD@vhash.io.

Hangcheng GBA Youth Entrepreneurship (Employment) Camp: Helping Returning Students Starting Jobs or Own Businesses

To help returning overseas students find jobs, and provide an entrepreneurial environment free of worries, Hangcheng, Bao’an District, Shenzhen established the Hangcheng GBA Youth Entrepreneurship (Employment) Camp. [10/27/20]

The Greater Bay Area / GBA Youth Entrepreneurship (Employment) Camp, open for only three months, proudly announces success in helping overseas students find jobs and start their own businesses. More than 50 job seekers and entrepreneurs have joined the Camp for consultation and classes, while 16 entrepreneurial teams have settled in. The Camp held activities during this first quarter, talent, entrepreneurship and policy meetings, lectures on intellectual property (IP) and legal ownership, and courses to help prepare graduates and resident teams to solve issues they will encounter as entrepreneurs. At the same time, Hangcheng GBA Youth Entrepreneurship (Employment) Camp has published articles addressing policies, questions and apprehensions, empowering overseas students returnees.

The Coronavirus outbreak of 2020 brought challenges to all countries; an International Labor Organization survey suggested that one-sixth of the world’s young people remain unemployed. The pandemic isn’t subsiding, and entrepreneurship and employment are tested to their limits. The employment situation for overseas students is even more worrying: these students cannot return to China and can only stay abroad; all the major enterprises have laid-off workers or reduced their salaries, making it difficult for the most competitive international students to find jobs, or face unemployment. The pandemic has impacted the original supply chain and capital chain for entrepreneurs, dealing many entrepreneurial teams fatal blows.

To reverse the social impact of the epidemic, the Chinese government has made employment and entrepreneurship a major task over this and the next few years. Various parts of China have issued favorable policies on employment and entrepreneurship, tried every possible means to stabilize and expand employment, and actively supported the masses’ Entrepreneurship and innovation. In terms of talent recruitment, Shenzhen Special Economic Zone has been at the forefront of the country. To help returning overseas students find jobs, and provide an entrepreneurial environment free of worries for returnees, the Hangcheng Sub-district, Bao’an District, Shenzhen, established the Hangcheng GBA Youth Entrepreneurship (Employment) Camp.

Bao’an District of Shenzhen is the heartland of the Guangdong-Hong Kong-Macao Greater Bay Area, close to the airport wharf and Bao’an International Airport. Bao’an is an important place of industry and innovation in Shenzhen and Guangdong Province. Bao’an District was selected eighth of the top 100 districts in China, In 2018; on March 4, 2020, Bao’an District ranked in the National Demonstration Base of New Industrialization by the Ministry of Industry and Information Technology. This is where the Hangcheng GBA Youth Entrepreneurship (Employment) Camp was founded.

Bao’an’s unique geographical and economic advantages will likely provide even more help for the entrepreneur. For overseas students, the main causes of employment difficulties are the lag of domestic employment news, maladjustment to the domestic environment, and lack of work experience. To assist with these issues, the Hangcheng GBA Youth Entrepreneurship (Employment) Camp, with it’s well established services system, provides the following:

– Help returning overseas students with an academic degree certification, in the form of settlement introductions, subsidy applications, and other guides;
– Resume optimization, interview guidance, career planning, and other help in updating the latest recruitment information in Bao’an District;
– Organizing enterprise introductory activities for overseas students to visit key enterprises in Bao’an, so as to help them better integrate into the domestic environment.
– Professional policy consultants and senior HR to solve overseas students’ employment problems.

As for returnee entrepreneurial teams, Hangcheng GBA Youth Entrepreneurship (Employment) Camp will surely become a leading choice to start a business back home. In addition to its Greater Bay Area location, the Hangcheng GBA Youth Entrepreneurship (Employment) Camp can provide 3-6 months of free office space for an entrepreneurial team. The space features a beautiful environment with complete support facilities: Additional to the office area are a reception area, roadshow hall, conference room, multi-function room, and other features. At the same time, it is equipped with a cafe, book bar, gym, and shower room, providing leisure space for entrepreneurs.

Free venues for entrepreneurs are provided in the early stage of entrepreneurship. Lectures on policy, business, finance, taxation, and legal affairs and invite experts to answer questions and doubts for entrepreneurs will be held time to time. Cooperation with investment institutions to provide financial support for entrepreneurs’ one-on-one investment in the middle stage of entrepreneurship, and match the appropriate follow-up incubation resources for entrepreneurs when the team matures.

To know more, please send a CV and project introduction to: bella@hexcubes.com

Contact: Eve@hexcubes.com
Telephone: +86 17603014024
Website: https://www.hexcubes.com
Address: Floor 2, Building 2, Baoxing Widsom City,
Qianjin No.2 Road, Baoan District, Shenzhen, China

Avance Clinical Wins MasterControl 2020 Innovation Excellence Award

The leading Australian CRO for biotechs, and Frost & Sullivan 2020 Asia-Pacific CRO Market Leadership Award winner, Avance Clinical today accepted the MasterControl 2020 Innovation Excellence Award in a virtual ceremony.

L-R: Priyanka Chamoli, Director Quality Assurance, Emma Woolman, Senior Compliance and Training Officer, Yvonne Lungershausen, Avance Clinical’s CEO, and Lisa Eglinton, Director Compliance and Training.

Avance Clinical made the announcement today at AusBiotech 2020 (28 – 30 October, 2020).
https://www.ausbiotechnc.org/

Avance Clinical CEO Yvonne Lungershausen said the company was very pleased to be awarded such recognition by MasterControl, a leader in the clinical digital management technology.

The MasterControl Clinical Excellence solution streamlines eTMF management and helps clients achieve real-time visibility into critical clinical processes across operational teams – all on one centralized platform. https://www.mastercontrol.com/clinical/

“The award acknowledges our leadership as Australia’s biotech CRO and it provides further confidence to our clients that we are serious about delivering quality clinical research services by being nimble and adaptive, and by utilising state-of-the-art systems that are compliant with industry standards, such as MasterControl eQMS,” said Yvonne Lungershausen.

“Avance Clinical invests significantly in the industry’s leading clinical technologies making it one of the most advanced CROs globally for digital clinical research management and eClinical solutions.”

On presenting the Innovation Excellence Award, MasterControl said the award recognises “the power of innovation and celebrates companies who feel the same way we do, who are not afraid to shed the status quo to find their own path and who push boundaries and spearhead important changes within their industries. Companies driven by innovation who truly live and breathe it.”

Avance Clinical Director Quality Assurance, Priyanka Chamoli, said:
“Receiving the award from MasterControl is a testament of our commitment to invest in our Quality Management System and to continually improve and strengthen it. This Award recognises and provides visibility to our efforts to push boundaries and adopt this significant change not just for the Quality Assurance department but across-the-board in the organisation.”

“MasterControl eQMS enables accurate, streamlined processes for Document Control and Training. Avance Clinical, which is on a significant growth trajectory, requires robust procedures as part of our QMS. MasterControl has allowed our staff to create/review and access our controlled documents in real-time and the automated link between different modules enables timely delivery of training.”

Avance Clinical Director Compliance and Training, Lisa Eglinton said:
“MasterControl Training Module provides a robust, user-friendly method for the delivery of role-specific training programs to all staff. The system provides a real-time indication of training status to Trainees and their Line Managers which ensures training compliance across the company.”

Avance Clinical is the leading Australian owned CRO that has been providing high-quality clinical research services fit for global regulatory standards to the local and international drug development industry for 20 years.

Considering Australia? Contact us about your next study. https://www.avancecro.com/eclinical-solutions/

See Image here http://bit.ly/AvanceClinicalMasterControl
(From left to right) Priyanka Chamoli, Director Quality Assurance, Emma Woolman, Senior Compliance and Training Officer, Yvonne Lungershausen, Avance Clinical’s CEO, and Lisa Eglinton, Director Compliance and Training.

About Avance Clinical www.avancecro.com

Australia’s Avance Clinical has more than 20-years of experience and is now one of Australia’s leading Contract Research Organizations.
Avance Clinical is committed to providing high-quality clinical research services with its highly-experienced team.
The collective pool of knowledge and experience at Avance Clinical continually grows through the careful selection of experts who also demonstrate passion in their chosen field.
Avance Clinical offers high-quality services in an established clinical trial ecosystem, that includes world-class Investigators and Sites able to access specialized patient groups.
Other benefits include:
1. The Government R&D grant means up to 43.5% rebate on clinical trial spend
2. eClinical solutions – speed and continuity
3. Site Initiation Visit (SIV) and Study Start achieved in 5 – 6 weeks
4. No IND required for clinical trials
5. Full GMP material is not mandated for Phase I clinical trials
6. Established clinical trial environment with world-class Investigators and sites
7. Established healthy subject databases and specialized patient populations
8. Five independent Phase 1 facilities across Australia including hospital-based units for critical care
9. Major hospitals with world-class infrastructures and dedicated Clinical Trial Units with a long track-record in FDA compliant research
10. Seasonal studies: Northern hemisphere Sponsors can conduct their studies year-round by taking advantage of Australia’s counter-flu and allergy seasons

Media Contact:
media@avancecro.com
Chris Thompson

Agilex Biolabs Client Shasqi Announces Click Chemistry Breakthrough with First-Ever Human Application in Launch of Clinical Program

Agilex Biolabs, Australia’s most advanced FDA-inspected specialist bioanalytical laboratory for clinical trials, congratulates client company Shasqi on the announcement of the first-ever application of click chemistry in humans, with the launch of the Company’s lead clinical candidate, SQ3370. Shasqi is the first Y Combinator-backed biotech company to reach clinical development.

San Francisco-based Shasqi said in the announcement:

First Patients Dosed in Phase 1 Clinical Study of SQ3370 for Advanced Solid Tumor Malignancies

Shasqi is First Y-Combinator Biotech Company to Reach First-in-Human Clinical Studies

Shasqi, a clinical-stage biotechnology company developing precision activated oncology therapeutics with its proprietary Click Activated Protodrugs Against Cancer (CAPACtm) Platform, announced today the first-ever application of click chemistry in humans, with the launch of the Company’s lead clinical candidate, SQ3370. Shasqi is the first Y Combinator-backed biotech company to reach clinical development.

The first two patients have been dosed in Shasqi’s Phase 1 clinical study of SQ3370 for the treatment of advanced solid tumors. SQ3370 is a novel investigational product that activates a non-toxic protodrug into a powerful chemotherapy agent, doxorubicin, precisely at a pre-injected tumor. SQ3370 is designed to allow substantially higher drug doses to be given to the patient, increasing tumor destruction while minimizing toxicity in the rest of the body.

“Shasqi is founded on the belief that one day we will be able to beat cancer without poisoning our bodies. We are excited to reach this milestone with our CAPAC Platform and the launch of Shasqi’s first clinical program,” said Jose M. Mejia Oneto, M.D., Ph.D., Founder and CEO of Shasqi.

The CAPAC Platform is a new therapeutic modality based on click chemistry, which leverages biocompatible chemical reactions, to activate protodrugs at a selected tumor that has been pre-injected with a biopolymer. The CAPAC platform is agnostic to tumor characteristics that can vary from patient to patient, such as biomarker expression and enzymatic activity, rendering it applicable to a broad array of tumor types. Additionally, the CAPAC Platform is highly modular and can be applied to a wide variety of cancer therapeutics in addition to doxorubicin.

“Doxorubicin has been proven effective for dozens of cancers, but severe side effects limit its use. Guiding it directly to the tumor while avoiding damage to the rest of the body may allow us to use doxorubicin and potentially many other drugs in a completely new and effective way for patients,” commented Wayne Saville, M.D., Chief Medical Officer of Shasqi. “Shasqi has taken a novel concept through a rigorous preclinical regulatory path all the way to treating patients in near-record time.”

“Shasqi was Y Combinator’s first therapeutic biotechnology investment and now the first of our life sciences companies to reach clinical development,” said Jared Friedman, Partner, Y Combinator. “We are extremely impressed by the team’s rapid advancement and capital-efficient execution. SQ3370 and CAPAC are not just a standard new small molecule, but rather a broad and powerful new platform leveraging state of the art science and materials to transform the treatment of cancer.”

SQ3370-001 (NCT04106492) is a multicenter, first-in-human, dose-escalation, Phase 1 clinical trial evaluating the safety and tolerability, pharmacokinetics, immune effects, and preliminary anti-tumor efficacy of SQ3370 in patients with locally advanced or metastatic solid tumor malignancies ineligible for standard-of-care therapy. The study is being conducted in the United States and Australia at multiple cancer centers, including MD Anderson Cancer Center and Stanford University. The study is expected to be completed in 2021. More information about the trial is available at: https://clinicaltrials.gov/ct2/show/NCT04106492.

See the announcement here. https://tinyurl.com/y2splohj

Agilex Biolabs is known internationally for its continued investment in the latest technology, and for attracting some of the leading scientists from Australia and around the world.

Agilex Biolabs, the only FDA-inspected lab of its type in the region, also features a rebate of up to 43.5% on clinical trial bioanalytical services spend as part of the Australian Government clinical trial attraction program.

Agilex Biolabs’ world-class bioanalytical facilities have OECD GLP Recognition with NATA (Australian Government OECD GLP Compliance monitoring authority) and ISO 17025 Accreditation for global recognition.

The company has recently expanded its labs by more than 30% to accommodate biotech demand from APAC and the USA. Watch the New Labs Walkthrough Video Here https://www.agilexbiolabs.com/new-labs-video

Agilex Biolabs specialises in bioanalysis of small molecules and biologics for PK, immunogenicity, biomarkers and immunological pharmacodynamics assessments utilising LC-MS/MS, immunoassay (Mesoscale, Gurolab, Luminex) and flow cytometry (BD FACSymphony A3, 20 colour cell analyser).

Agilex also offers pharmacodynamics services that include immunobiology services using the latest state-of-the-art technology to support immunology, cell biology and mode of action assays, including:
– Immunophenotyping
– Receptor occupancy
– Cytokine release assays (whole blood or PBMC stimulation assays) and cytokine/biomarker profiling
– PBMC assays and cellular mechanism of action assays (eg: ADCC)

Agilex Biolabs has more than 90 staff including 65 dedicated laboratory staff, and annually support more than 80 clinical trials. This year they will analyse more than 60,000 samples for pharma/biotechs companies from US, Europe and APAC.

Please Book a Briefing with us before you start your next clinical trial. https://calendly.com/agilexbiolabs/15min

About Agilex Biolabs https://www.agilexbiolabs.com/

Agilex Biolabs, Australia’s leading bioanalytical laboratory, has more than 20 years’ experience in performing regulated bioanalysis, including quality method development, method validation and sample analysis services. We have successfully supported hundreds of preclinical and clinical trials around the world where customers choose Australia for the streamlined regulatory process and access to the world’s most attractive R&D rebate of more than 40% on clinical trial work conducted in Australia.

We offer services for both small molecules and biologics for PK, immunogenicity (PD) and biomarker bioanalysis utilising the two platforms of LC-MS/MS and Immunoassay.

Agilex Biolabs Media Contact:
Media@AgilexBiolabs.com
Kate Newton

Shasqi media contact:
David Rosen, Argot Partners
media@shasqi.com
+1 (212) 600-1902

Tianzow Breeding (1248.HK) harnesses a favourable industry situation by bringing three cornerstone investors into the market

According to SCMP: According to the recently announced third quarter performance forecasts, all major listed breeding companies have recorded varying degrees of profit growth. Meanwhile, Huaan Securities believes the price of live pigs has stabilized and rebounded, and is expected to remain relatively high in 2020-2021. In terms of new IPOs, Sichuan Tianzow Breeding Technology Co., Ltd. (1248.HK), a newcomer in the industry, began its public offering period from October 29 to November 6 and has priced its shares at a price ranging between HK$26.00 to HK$38.80. The company plans to become listed publicly on the Hong Kong Main Board on November 16.

Tianzow Breeding mainly provides high-quality breeding stock and market hogs, as well as related ancillary products and services. According to a report by China Insights Consultancy, in 2019, the company ranked first among all breeding stock farming companies in China in terms of breeding stock sales revenue and was also one of the top 50 market hogs companies in China. Tianzow Breeding has reportedly entered cornerstone investment agreements with the following cornerstone investors: controlling shareholder of Fujian Anjoy Foods Co., Ltd. (603345.SH), Xinjiang Guoli Minsheng Equity Investment Co., Ltd., Fuhui Capital Investment Limited, which is wholly-owned by China Lesso Group Holdings Limited (2128.HK), and Mr. Zhong Zhaomin, director of Eastern Marathon Investment Management (Hong Kong) Company Limited, subscribing a total of approximately HK$150 million. The strong support of cornerstone investors with profound investment and food-related backgrounds shows that the capital market has strong confidence in Tianzow Breeding’s own competitive strengths and development.

Tianzow Breeding has an abundance of genetic resources. With continuous research, experimentation and testing, it has established and continuously optimized in-depth pig breeding and pig farming know-how, maintaining an advantageous position in the scattered Chinese pig breeding industry. The company also utilizes its “Tianzow Cloud Smart Pig Farming Management System” to not only promote the efficient prevention and control of diseases, but also to conduct continuous analysis of production data to improve breeding efficiency and increase productivity.

Additionally, Tianzow Breeding has a sufficient supply capability of breeding stock and a wide geographical coverage, providing customers in different locations with breeding stock and market hogs in a cost-effective manner. As at the Latest Practicable Date, the company has established 47 pig farms in Southwest, Northeast and Northwest regions of China; and the maximum output capacity reached approximately 300,000 heads as of January 1, 2020. In the fiscal year 2017, the fiscal year 2018, the fiscal year 2019 and the first four months of 2020, the company sold approximately 238.1 thousand, 224.7 thousand, 277.4 thousand and 73.8 thousand heads, respectively, to its customers.

According to an analysis by China Insights Consultancy, China’s market hog market will welcome a new round of cyclical growth. Its market size is estimated to reach 1,486 billion yuan in 2024, and its compound annual growth rate will reach 4.4% from 2019 to 2024. Tianzow Breeding is expected to seize its listing as an opportunity for industry growth, further strengthening of its brand and products, expanding production and supply capabilities, and assisting the pig breeding value chain by improving operational efficiency with modern pig farming.

Raffles Announces 2020 Fiscal Year-End Financial Results

Raffles Financial Group Limited (CSE: RICH) (FSE: 4VO) (OTC: RAFFF) (“Raffles” or “the Company”) today announces its financial results for the fiscal year ended June 30, 2020, highlighted by revenue of $8,866,672 and adjusted comprehensive income before other items and income tax expenses of $12,220,573. All amounts expressed are in Singapore dollars.

2020 Financial Highlights:
– Total Revenue of $8,866,672 (2019: $11,533,334)
– Adjusted comprehensive income before other items and income tax expenses3 of $12,220,573 (2019: $10,750,652)
– Cash Flow from operations of $7,044,654 (2019: $11,002,734)
– The Company generated cash inflow from financing activities of $20,296,000 (2019: cash outflow of $8,900,000) related to the completion of a private placement for gross proceeds of $20,296,000.

Comparative Summary of Key Financial Metrics for 2019 and 2020
2020 – 2019
Revenue $8,866,672 $11,533,334
Unrealized gain on investments $4,748,139 –
Operating expenses(*1) $1,565,443 $782,682
Listing expenses for RTO(*2) $6,052,280 –
Adjusted comprehensive income before other items and income tax expenses(*3) $12,220,573 $10,750,652
Net Income (Loss) ($425,229) $9,560,301

(*1) Operating expenses do not include interest, taxes, depreciation (including impairment of intangible assets) and amortization, and other non-recurring Items and non-cash accounting expenses.
(*2) Listing expense relates to the RTO in the amount of $6,052,280, which comprised of a non-cash acquisition consideration of $5,479,920 recognised under IFRS 3 in accounting for the reverse take over transaction (“RTO”).
(*3) Adjusted comprehensive income before other items and income tax expenses equals income before other items and income tax expenses plus other comprehensive income includes Foreign currency translation and unrealized gain on investments.

Review of 2020
The Company’s sole operating subsidiary, Raffles Financial Private Limited (“RFP”), first appeared in the second quarter of the calendar year 2020, marking the beginning of the Company tapping into the corporate finance advisory segment exclusively. From a financial standpoint, the Company was able to exceed its revenue and earning objectives for the year. From an operational standpoint, the Company disposed its old business and continued to make inroads into the Asia financial market through its services provided by RFP. The highly customisable service provided to its small to medium clients, coupled with its unique professional and low-cost service, are value-propositions that continue to resonate with and account for its adoption rate among industry players.

Outlook for 2021
– Significant opportunities for Raffles as many business owners and investors are seeking solutions to their financial situations amid the COVID-19 pandemic;
– Rising wave of acquisitive Chinese companies venturing beyond their national borders has created an uptick in outbound transactions;
– Asia-Pacific is expected to continue to dominate global IPO activity year-to-date in 2020 by volume.

Future Plans
– To expand our market by adding more Provincial Representatives;
– To enter into Strategic Partnerships and cooperation with international banks, venture capital firms, incubators, etc.;
– To invest in businesses that meet our investment criteria and guidelines;
– To strengthen our market liquidity and shareholder base.

Fiscal 2020 Financial Results Summary
The Company generated revenues of $8,866,672, which was derived from two major service segments, namely financial advisory service and licensing service (compared to $11,533,334 in fiscal 2019). The difference in revenue between fiscal 2019 and fiscal 2020 can be attributed to:

– the COVID-19 pandemic which caused travel restrictions and shutdowns that delayed and suspended the delivery of our advisory services (namely Re-structuring & Corporate Finance Advisory (“RCF”), IPO & Global Fund Raising Advisory (“IRS”) and Fund, Family Office, Trust Advisory (“FOT”)), and created difficulties for the Company to service clients in most of the major cities in which the Company operates including, among others, China, Hong Kong and Singapore;
– there were no FOT advisory service agreements entered into with clients so no fee income from FOT services during 2020 ($1,500,000 in 2019);
– suspension in licensing services with clients pursuant to force majeure clause in response to the COVID-19 outbreak since January 2020. The Company had agreed with its clients (the Regional Representatives) who were based in the PRC to suspend the contracted licensing services commencing in January 2020. The COVID-19 outbreak had a significant impact not only on the Company itself but also the Company’s clients in PRC, as they had been hindered from performing their obligations under their service agreements due to the lockdown imposed by the local authorities and market downturn during and after the COVID-19 outbreak. Consequently, licensing services with clients was suspended until the clients can fully resume operations.

Administrative expenses for fiscal 2020 amounted to $1,565,443, compared to $782,682 in 2019. The difference between fiscal 2019 and fiscal 2020 was mainly due to:

– a non-cash item of share-based compensation of $297,610 pertaining to stock options granted to certain management and directors of the Company (2019: nil);
– a business development and marketing expenses amounting to $205,727 (2019: nil);
– increased professional fees, directors fee and staff costs arising from the RTO transaction and incurred after listing.

The comprehensive income for the year was $4,494,115 compared to $9,560,301 in 2019.

Excluding the listing expense related to the RTO in the amount of $6,052,280 (it comprised of a non-cash consideration of $5,479,920 recognised under IFRS 3 in accounting for the RTO), the Company made a comprehensive income of $10,546,395 in 2020 (comprising of operating profits of $5,627,051 and other comprehensive Income of $4,919,344). In 2019, the Company had a comprehensive income of $9,560,301.

Full details of the Company’s 2020 financial results can be found in the Audited Consolidated Financial Statements and Management’s Discussion and Analysis (MD&A) for the years ended June 30, 2020, which are available at www.sedar.com.

About Raffles Financial Group Limited (CSE: RICH) (FSE: 4VO) (OTC: RAFFF)
Raffles Financial Pte. Ltd. (a wholly-owned subsidiary of Raffles Financial Group Limited) is an exempt corporate finance advisory firm, registered with the Monetary Authority of Singapore, which provides public listing advisory and arrangement services. Raffles Financial serves as advisor for family trusts, family offices and investment funds. Please visit www.rafflesfinancial.co for more information.

For more information, please contact:
Cathy Hume, Investor Relations
Phone: 416-868-1079 x 231
Email: cathy@chfir.com

Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release. Certain statements contained in this release may constitute “forward-looking statements” or “forward-looking information” (collectively “forward-looking information”) as those terms are used in Canadian securities laws. These statements relate to future events or future performance. The use of any of the words “could”, “intend”, “expect”, “believe”, “will”, “projected”, “estimated”, “anticipates” and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on the Company’s current belief or assumptions as to the outcome and timing of such future events. Actual future results may differ materially. In particular, this release contains forward-looking information relating to the business of the Company, the anticipated partnerships with financial institutions worldwide and the growth potential through Province Representatives. The forward-looking information contained in this release is made as of the date hereof and the Company is not obligated to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. Because of the risks, uncertainties and assumptions contained herein, investors should not place undue reliance on forward-looking information. The foregoing statements expressly qualify any forward-looking information contained herein.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/67117

Biotechs get scalable early to late phase clinical offering from Avance Clinical and Cromos Pharma – announced at Bio-Europe 2020

The collaboration allows biotechs to quickly start their pre-IND early phase studies in Australia, then expand to Central/Eastern Europe to access the large patient populations for their Phase 2 and 3 studies.

Two dominant regional contract research organizations (CRO), Avance Clinical and Cromos Pharma, with operations in Australia and Central/Eastern Europe, respectively, are successfully collaborating on a scalable clinical solution for biotechs.

Importantly, the AU/EU model allows biotechs to keep their data and trial management in Australia, and take advantage of the Australian cash rebate of up to 43.5% on clinical trial costs, throughout all study phases, across both regions.

“We are very excited about this model that seamlessly incorporates two of the most compelling and complementary international clinical research hubs for our biotech clients from early to late phase studies,” said Yvonne Lungershausen, CEO of Avance Clinical.

“Our eClinical and early phase expertise is well augmented by Cromos Pharma’s track record in late stage trials and rapid enrollment capabilities,” she continued.

“We have been collaborating with Avance Clinical and referring clients to each other for years,” remarked Vlad Bogin, CEO of Cromos Pharma.

“But it was a true Eureka moment when we realized that combining Australia’s 43.5% tax rebate with Central/Eastern Europe’s unbeatable recruitment rates is a paradigm shift in how clinical trials should be conducted,” he concluded.

Cromos Pharma can access hundreds of millions of patients via more than 2,500 sites in Central/Eastern Europe.

About Cromos Pharma, www.cromospharma.com

Cromos Pharma provides tailored and effective clinical trial solutions to support the development of drugs that transform healthcare. An international CRO with over 15 years’ experience, we offer fully integrated services performing all aspects of clinical trials in all clinical phases and in a wide range of therapeutic areas. Cromos Pharma delivers rapid recruitment and excellent patient retention as well as expert study design and management. Cromos Pharma has strong regional experience in Central and Eastern Europe with global coverage provided by its US bases in Portland, Oregon and Miami, Florida. Cromos Pharma’s European HQ is in Dublin, Ireland. At Cromos Pharma, we know how important your product is. When the stakes are this high, you need a high-performance partner.
Key benefits:
– International expertise combined with in-depth regional knowledge in Central and Eastern Europe (300+ clinical trials conducted in 70+ indications).
– Extensive PI/site and patient network (40,000+ patients enrolled from nearly 2,500 trial sites).
– Unparalleled patient recruitment – our team met or shortened project timelines in 95% of conducted trials.
– Responsible recruitment is supported by Cromos Pharma’s “No Patients-No Payments” initiative – a unique risk-sharing program.
– Extremely short startup timelines (e.g. Georgia where we assure a study launch in less than 2 months).
– Expertise in innovative, generics and biosimilar global studies (NDAs, ANDAs, BLAs, 505b2).
– Regulatory inspections and audits that attest to the highest quality of data: EMA in 2019 (1-week oncology site inspection); FDA in 2017 (2-week oncology site inspection).
– Clinical Development Strategy – we provide expert guidance on study design, favorable venues, local and global landscape to improve study outcomes.

About Avance Clinical, www.avancecro.com

Australia’s Avance Clinical has more than 20-years of experience and is now one of Australia’s leading Contract Research Organizations for biotechs. Avance Clinical is committed to providing high-quality clinical research services with its highly-experienced team.
The collective pool of knowledge and experience at Avance Clinical continually grows through the careful selection of experts who also demonstrate passion in their chosen field.
Avance Clinical offers high-quality services in an established clinical trial ecosystem, that includes world-class Investigators and Sites able to access specialized patient groups.
Other benefits include:
1. The Government R&D grant means up to 43.5% rebate on clinical trial spend
2. eClinical solutions capabilities – speed and continuity
3. Site Initiation Visit (SIV) and Study Start achieved in 5 – 6 weeks
4. No IND required for clinical trials
5. Full GMP material is not mandated for Phase I clinical trials
6. Established clinical trial environment with world-class Investigators and sites
7. Established healthy subject databases and specialized patient populations
8. Five independent Phase 1 facilities across Australia including hospital-based units for critical care
9. Major hospitals with world-class infrastructures and dedicated Clinical Trial Units with a long track-record in FDA compliant research
10. Seasonal studies: Northern hemisphere Sponsors can conduct their studies year-round by taking advantage of Australia’s counter-flu and allergy seasons

Media Contacts:
Avance Clinical
Chris Thompson: media@avancecro.com

Cromos Pharma
Nicola Donnelly: media@cromospharma.com

Endpoints News Presents “Why Australia and Agilex Biolabs for your Next Clinical Trial” for Bio Europe 2020

Agilex Biolabs, Australia’s most advanced FDA-inspected specialist bioanalytical laboratory for clinical trials, has partnered with Endpoints News to produce an exceptional step-by-step webinar on how to run your trial in Australia, and why Agilex Biolabs is the leading biolabs partner. Watch here (no charge) https://tinyurl.com/yyzf6o44

Agilex Biolabs is known internationally for its continued investment in the latest technology, and for attracting some of the leading scientists from Australia and around the world.

The webinar was launched as part of Agilex Biolabs’ presence at Bio Europe. Click here to meet Agilex Biolabs at Bio Europe via the partneringone tool. https://informaconnect.com/bio-europe-virtual/

Dr Kurt J. Sales, Agilex Biolabs Director, Immunoassay B.Sc (Med)(Hons), M.Sc, PhD, PGCM led with a presentation detailing the rapid trials process in Australia.

He stressed the importance of talking to Agilex Biolabs early, even before selecting a CRO and other partners, due to the depth of advice the scientific team can offer Sponsors, and the time it can take to develop some assays.

The webinar also featured leading clinical research specialist Jane Kelly who has 27 years in the industry. She is CEO of CMAX Clinical Research, a major Phase 1 Unit located near Agilex Biolabs.

Kelly pointed to the significant advantages of having the biolabs close to the Phase 1 Unit in terms of sample transfer and data turnaround, and offering a seamless clinical experience for Sponsors.

Agilex Biolabs, the only FDA-inspected lab of its type in the region, also features a rebate of up to 43.5% on clinical trial bioanalytical services spend as part of the Australian Government clinical trial attraction program.

Agilex Biolabs’ world-class bioanalytical facilities have OECD GLP Recognition with NATA (Australian Government OECD GLP Compliance monitoring authority) and ISO 17025 Accreditation for global recognition.

The company has recently expanded its labs by more than 30% to accommodate biotech demand from APAC and the USA. Watch the New Labs Walkthrough Video Here https://www.agilexbiolabs.com/new-labs-video

Agilex Biolabs specialises in bioanalysis of small molecules and biologics for PK, immunogenicity, biomarkers and immunological pharmacodynamics assessments utilising LC-MS/MS, immunoassay (Mesoscale, Gurolab, Luminex) and flow cytometry (BD FACSymphony A3, 20 colour cell analyser).

Agilex also offers pharmacodynamics services that include immunobiology services using the latest state-of-the-art technology to support immunology, cell biology and mode of action assays, including:

  • Immunophenotyping
  • Receptor occupancy
  • Cytokine release assays (whole blood or PBMC stimulation assays) and cytokine/biomarker profiling
  • PBMC assays and cellular mechanism of action assays (eg: ADCC)

Agilex Biolabs has more than 90 staff including 65 dedicated laboratory staff, and annually support more than 80 clinical trials. This year they will analyse more than 60,000 samples for pharma/biotechs companies from US, Europe and APAC.

Please Book a Briefing with us before you start your next clinical trial. https://calendly.com/agilexbiolabs/15min

Australia: +61 8 8302 8777 | China: +86 21 8036 9483 | South Korea: +82 80 812 1255 | USA: +1 800 247 1909

About Agilex Biolabs https://www.agilexbiolabs.com/

Agilex Biolabs, Australia’s leading bioanalytical laboratory, has more than 20 years’ experience in performing regulated bioanalysis, including quality method development, method validation and sample analysis services.

Agilex Biolabs has successfully supported hundreds of preclinical and clinical trials around the world where customers choose Australia for the streamlined regulatory process and access to the world’s most attractive R&D rebate of more than 40% on clinical trial work conducted in Australia.

The company offers services for both small molecules and biologics for PK, immunogenicity (PD) and biomarker bioanalysis utilising the two platforms of LC-MS/MS and Immunoassay.

Agilex Biolabs operates a fully quality-assured laboratory ensuring that, within the principles of GLP, assays are validated to the latest FDA/EMA guidance and study samples are assayed and reported to the sponsor’s desired format using WATSON LIMS. Laboratory certifications include OECD GLP and ISO/IEC17025.

Media Contact:
Media@AgilexBiolabs.com
Kate Newton

Wintermar Offshore (WINS:JK) Reports 9M2020 Results

Wintermar Offshore Marine (WINS:JK) has announced results for 9M2020. Wintermar’s Owned Vessel revenue for 9M2020 was 17% lower YOY at US$24.6 million and there was a slight improvement on a quarterly basis in 3Q2020 compared to 2Q2020.

–Owned Vessel Division
For the 9M2020 period, Owned Vessel Division recorded a gross loss of US$2.8 million, largely due to cancellations and postponement of contracts caused by the pandemic. Cost efficiency measures and a streamlining of the fleet undertaken since last year led to a 14% YOY decline in Owned Vessel direct expenses, which helped mitigate some of the losses.

On a quarterly basis, revenue for 3Q2020 was slightly improved as compared to 2Q2020 while direct expenses fell.

Measures taken to improve cost efficiency resulted in a 14% reduction in direct expenses for Owned Vessels. Fuel costs dropped sharply by 71% YOY while depreciation fell by 14% YOY due to the sale of 4 vessels in the period 1 January 2020 until 30 September 2020. However, due to the cost of extra precautions taken to ensure the health and safety of crew and clients crewing costs were only 3% lower YOY for 9M2020.

–Chartering and Other Services
Chartering was also negatively affected, contributing US$0.4 million to gross profit as compared to US$1 million in 9M2019. Other Services experienced a similar decline and contributed US$0.3 million to gross profit for 9M2020.

–Indirect Expenses and Operating Loss
Overall, indirect expenses were 15% lower YOY, totaling US$4.5 million for 9M2020. The biggest contributor to these savings was a 15% YOY decline in staff salaries. This was due to lower headcount as well as a voluntary salary reduction supported by all levels of management and staff to mitigate the impact of the pandemic. Marketing and travelling expenses fell YOY by 74% and 43% respectively while lower depreciation also contributed to the cost reduction for 9M2020 compared to 9M2019.

The Operating Loss was 17% YOY higher at US$6.5 million for 9M2020.

–Other Income, Expenses and Net Attributable profit
Interest expenses fell by 27% YOY to US$2.5 million, largely due to lower debt as the Company paid off US$5.7 million of bank loans over the past 9 months. Vessel sale proceeds of US$4,9 million added US$1.2 million to other income, while share of associate companies’ losses widened to US$0.4 million from US$0.02 million.

For the nine months ending 30 September 2020, the net loss attributable to shareholders totalled US$7.4 million compared to US$5.7 million in 9M2019.

EBITDA for 9M2020 was US$9 million, compared to US$12.5 million booked in 9M2019.

–Oil & Gas Industry
Activity was slow during 3Q2020, as the world continued to grapple with measures to control the COVID-19 pandemic. In South East Asia, charter rates have been stagnant and are unlikely to drop much further as they are barely covering cash costs. However, leading indicators for oil and gas are turning more positive.

In its October report, the International Energy Agency (IEA) projected that world demand for oil would return to 96.1 million bpd by Q42020 compared to an average of 100.1 million bpd for 2019. This represents a sharp recovery from 2Q2020 where global oil demand fell to the lowest point at 83 million bpd. On the supply side, oil and gas production has been hit hard as many Exploration and Production companies have cut back on investments due to financial pressures. OPEC+ has shown high compliance in maintaining lower production. If IEA projections are achieved, excess oil inventories may be drawn down by end of 2020, which is potentially good news for oil price stability and strength in 2021.

A recent study by Rystad Energy has concluded that deepwater drilling costs have fallen to US$50/barrel, lower than US shale production costs. Should oil prices recover, there are several potential offshore projects in SE Asia which could provide increased gas supply.

SKK MIGAS, Indonesia’s regulator for the upstream oil and gas sector, has just reiterated in October 2020 their plans to boost oil and gas production to achieve their target of 1 million bpd by 2030 from 746,000 bpd in 2020. Since Indonesia has several discovered but undeveloped fields, this would actually be an achievable goal if the government is able to deliver on their plans for enhanced oil recovery and exploration.

–Strategy and Outlook
As countries have started to ease their COVID-19 restrictions on travel and business activities, there has been a gradual but steady recovery in oil and gas demand. China, which was early to emerge from lockdown, has shown a sharp recovery in economic growth.

The economic slump and spike in unemployment worldwide is being addressed through stimulus packages proposed by governments around the world. The threat of a resurgence of the virus seems to be handled with more localized lockdown measures to limit the harsh economic effects of COVID-19 “lockdown” restrictions. All this points to a gradual recovery of demand for oil in the coming year.

Although 2020 results will continue to be plagued by the pandemic’s effect on reducing oil demand, there has started to be more tendering activity in 4Q2020 which is indicative of better times in 2021.

Rystad Energy research is projecting growth in South East Asian gas production. Wintermar has been building up a presence in Malaysia, Brunei and Myanmar for the past few years, as we position the Company to be a major player in Asia.

Contracts on hand as at end September 2020 amount to US$70 million.

About Wintermar Offshore Marine Group
Wintermar Offshore Marine Group (WINS.JK), developed over nearly 50 years with a track record of quality that is both a source of pride and responsibility that we are dedicated to upholding, and sails a fleet of more than 48 Offshore Support Vessels ready for long term as well as spot charters. All vessels are operated by experienced Indonesian crew, tracked by satellite systems and monitored in real time by shore-based Vessel Teams.

Wintermar is the first shipping company in Indonesia to be certified with an Integrated Management System by Lloyd’s Register Quality Assurance, and is currently certified with ISO 9001:2015 (Quality), ISO14001:2015 (Environment) and OHSAS 18001:2007 (Occupational Health and Safety). For more information, please visit www.wintermar.com.

Contact:

Ms. Pek Swan Layanto, CFA  
Investor Relations
PT Wintermar Offshore Marine Tbk
Tel: +62-21 530 5201 Ext 401
Email: investor_relations@wintermar.com